Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Tonix Pharma ( (TNXP) ).
On September 17, 2025, Tonix Pharmaceuticals announced the in-licensing of worldwide rights to TNX-4800, a long-acting human monoclonal antibody targeting Lyme disease. Developed by UMass Chan Medical School, TNX-4800 offers a novel approach by providing pre-exposure prophylaxis against Lyme disease with a single subcutaneous administration, bypassing the need for multidose vaccines. This strategic move positions Tonix to advance TNX-4800 through clinical trials, aiming for a Biologics Licensing Application submission to the FDA, potentially impacting the market for Lyme disease prevention.
The most recent analyst rating on (TNXP) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s overall score is driven by strong corporate events, particularly the FDA approval of Tonmya, which significantly boosts its market potential. However, challenges in profitability and valuation weigh down the score. Mixed technical indicators suggest cautious optimism.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on the development of innovative therapies. The company is engaged in creating products that address unmet medical needs, particularly in the areas of immunology and infectious diseases.
Average Trading Volume: 1,429,845
Technical Sentiment Signal: Sell
Current Market Cap: $243.3M
See more data about TNXP stock on TipRanks’ Stock Analysis page.